Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Free Cash Flow (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Free Cash Flow for 7 consecutive years, with -$5.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Free Cash Flow rose 23.22% to -$5.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$33.1 million, a 30.33% increase, with the full-year FY2024 number at -$33.1 million, up 30.33% from a year prior.
  • Free Cash Flow was -$5.8 million for Q4 2024 at Actinium Pharmaceuticals, up from -$12.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $27.6 million in Q2 2022 to a low of -$15.2 million in Q1 2023.
  • A 4-year average of -$5.8 million and a median of -$6.6 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 695.22% in 2022, then crashed 161.8% in 2023.
  • Actinium Pharmaceuticals' Free Cash Flow stood at -$5.1 million in 2021, then tumbled by 54.28% to -$7.8 million in 2022, then increased by 3.9% to -$7.5 million in 2023, then rose by 23.22% to -$5.8 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Free Cash Flow are -$5.8 million (Q4 2024), -$12.0 million (Q3 2024), and -$8.0 million (Q2 2024).